222 related articles for article (PubMed ID: 11939605)
1. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment.
Arai S; Margolis J; Zahurak M; Anders V; Vogelsang GB
Biol Blood Marrow Transplant; 2002; 8(3):155-60. PubMed ID: 11939605
[TBL] [Abstract][Full Text] [Related]
2. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease.
MacMillan ML; Weisdorf DJ; Davies SM; DeFor TE; Burns LJ; Ramsay NK; Wagner JE; Blazar BR
Biol Blood Marrow Transplant; 2002; 8(1):40-6. PubMed ID: 11858189
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease.
Cragg L; Blazar BR; Defor T; Kolatker N; Miller W; Kersey J; Ramsay M; McGlave P; Filipovich A; Weisdorf D
Biol Blood Marrow Transplant; 2000; 6(4A):441-7. PubMed ID: 10975513
[TBL] [Abstract][Full Text] [Related]
4. Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease.
Kennedy GA; Butler J; Western R; Morton J; Durrant S; Hill GR
Bone Marrow Transplant; 2006 Jun; 37(12):1143-7. PubMed ID: 16699531
[TBL] [Abstract][Full Text] [Related]
5. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
[TBL] [Abstract][Full Text] [Related]
6. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
7. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin.
Khoury H; Kashyap A; Adkins DR; Brown RA; Miller G; Vij R; Westervelt P; Trinkaus K; Goodnough LT; Hayashi RJ; Parker P; Forman SJ; DiPersio JF
Bone Marrow Transplant; 2001 May; 27(10):1059-64. PubMed ID: 11438821
[TBL] [Abstract][Full Text] [Related]
8. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
Srinivasan R; Chakrabarti S; Walsh T; Igarashi T; Takahashi Y; Kleiner D; Donohue T; Shalabi R; Carvallo C; Barrett AJ; Geller N; Childs R
Br J Haematol; 2004 Mar; 124(6):777-86. PubMed ID: 15009066
[TBL] [Abstract][Full Text] [Related]
9. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
10. The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies.
Sakellari I; Batsis I; Bousiou Z; Mallouri D; Constantinou V; Gavriilaki E; Smias C; Yannaki E; Kaloyannidis P; Papaioannou G; Stavroyianni N; Syrigou A; Sotiropoulos D; Fylaktou A; Tsompanakou A; Saloum R; Anagnostopoulos A
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):658-666. PubMed ID: 28716402
[TBL] [Abstract][Full Text] [Related]
11. The response-guided ATG treatment provides a survival benefit and KPS recovery for patients with steroid refractory acute GVHD: The Nagasaki Transplant Group Experience.
Fujioka M; Itonaga H; Furumoto T; Kasai S; Sakamoto H; Kitanosono H; Kato T; Horai M; Sato S; Sawayama Y; Taguchi J; Imaizumi Y; Hata T; Yoshida S; Moriuchi Y; Miyazaki Y
Transpl Immunol; 2021 Aug; 67():101417. PubMed ID: 34058354
[TBL] [Abstract][Full Text] [Related]
12. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
Russell JA; Turner AR; Larratt L; Chaudhry A; Morris D; Brown C; Quinlan D; Stewart D
Biol Blood Marrow Transplant; 2007 Mar; 13(3):299-306. PubMed ID: 17317583
[TBL] [Abstract][Full Text] [Related]
13. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.
Bacigalupo A; Lamparelli T; Barisione G; Bruzzi P; Guidi S; Alessandrino PE; di Bartolomeo P; Oneto R; Bruno B; Sacchi N; van Lint MT; Bosi A;
Biol Blood Marrow Transplant; 2006 May; 12(5):560-5. PubMed ID: 16635791
[TBL] [Abstract][Full Text] [Related]
14. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin.
McCaul KG; Nevill TJ; Barnett MJ; Toze CL; Currie CJ; Sutherland HJ; Conneally EA; Shepherd JD; Nantel SH; Hogge DE; Klingemann HG
J Hematother Stem Cell Res; 2000 Jun; 9(3):367-74. PubMed ID: 10894358
[TBL] [Abstract][Full Text] [Related]
15. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M
Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768
[TBL] [Abstract][Full Text] [Related]
16. Low incidences of acute and chronic graft-versus-host disease after unrelated bone marrow transplantation with low-dose anti-T lymphocyte globulin.
Hatanaka K; Fuji S; Ikegame K; Kato R; Wake A; Hidaka M; Ito T; Inoue M; Nagatoshi Y; Takami A; Uike N; Sakamaki H; Yabe H; Morishima Y; Suzuki R; Atsuta Y; Fukuda T
Int J Hematol; 2012 Dec; 96(6):773-80. PubMed ID: 23132596
[TBL] [Abstract][Full Text] [Related]
17. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome.
Weisdorf D; Haake R; Blazar B; Miller W; McGlave P; Ramsay N; Kersey J; Filipovich A
Blood; 1990 Feb; 75(4):1024-30. PubMed ID: 2302454
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
[TBL] [Abstract][Full Text] [Related]
19. Additional stem cell therapy for graft failure after allogeneic bone marrow transplantation.
Min CK; Kim DW; Lee JW; Min WS; Kim CC
Acta Haematol; 2000; 104(4):185-92. PubMed ID: 11279309
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
Kröger N; Zabelina T; Renges H; Krüger W; Kordes U; Rischewski J; Schrum J; Horstmann M; Ayuk F; Erttmann R; Kabisch H; Zander AR
Ann Hematol; 2002 Nov; 81(11):627-31. PubMed ID: 12454700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]